Emricasan NEW
| Price | $37 | $53 | $87 |
| Package | 1mg | 2mg | 5mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Emricasan | CAS No.: 254750-02-2 |
| Purity: 99.11% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Emricasan |
| Description | Emricasan (IDN-6556) is a pan-caspase inhibitor with irreversible properties. Emricasan has anti-inflammatory and anti-apoptotic activity and can be used in the treatment of infections and liver failure, etc. Emricasan also inhibits Zika virus infections. |
| Cell Research | Astrocytes are mock-infected, treated with DMSO or treated with 2 μM niclosamide, 92 μM PHA-690509, 9 μM emricasan, or a combination of 92 μM PHA-690509 and 9 μM emricasan for 1 h before infection with PRVABC59 (MOI = 0.5). Cells are fixed 24 h after infection and stained for ZIKVE and nuclei.(Only for Reference) |
| In vitro | METHODS: Primary rat cirrhotic hepatocytes were treated with Emricasan (50 μM) for 24 h, and mRNA expression levels were measured. RESULTS: Emricasan directly improved the expression of hepatocyte-specific markers. [1] METHODS: Human cervical cancer cells HeLa were pretreated with Emricasan (10 μM) for 1 h, then treated with vincristine (20 nM) for 44 h. Cell death was detected by Flow Cytometry. RESULTS: Emricasan eliminated 95% of vincristine-mediated cell death. [2] |
| In vivo | METHODS: To study the effects on chronic liver disease, Emricasan (10 mg/kg, 0.9% dimethylcarboxycellulose) was administered orally once daily for seven days to rats with advanced cirrhosis due to chronic CCl4 administration. RESULTS: Emricasan ameliorated hepatic sinusoidal microvascular dysfunction in cirrhotic patients, resulting in significant improvement in fibrosis, portal hypertension and liver function. [1] METHODS: To investigate the effects on cirrhosis, Emricasan (10 mg/kg) was administered intraperitoneally once daily for 10-20 days to C57BL/6 mice with secondary biliary cirrhosis induced by bile duct ligation (BDL). RESULTS: Emricasan treatment improved survival and portal hypertension (PHT) in a mouse model of long-term BDL. [3] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : < 1 mg/mL (insoluble or slightly soluble) DMSO : 50 mg/mL (87.8 mM) Ethanol : 93 mg/mL (163.3 mM) |
| Keywords | Inhibitor | IDN 6556 | Caspase | PF-03491390 | Influenza Virus | IDN6556 | PF03491390 | inhibit | Emricasan |
| Inhibitors Related | Curcumin | Crystal Violet |
| Related Compound Libraries | Highly Selective Inhibitor Library | Bioactive Compound Library | Drug Repurposing Compound Library | Anti-Viral Compound Library | Anti-Aging Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $9.00/10g |
VIP1Y
|
Hebei Kangcang new material Technology Co., LTD
|
2024-03-27 | |
| $1.10/1g |
VIP4Y
|
Dideu Industries Group Limited
|
2021-08-17 | |
| $2.00/1kg |
VIP7Y
|
Career Henan Chemical Co
|
2018-12-24 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY